Cart
sales@molnova.com
Saracatinib
CAS No. 379231-04-6
Saracatinib ( AZD0530;AZD-0530;AZD 0530 )
Catalog No. M14308 CAS No. 379231-04-6
A potent, highly selective, orally available, dual Src/Abl kinase inhibitor with IC50 of 2.7, 4, 4 and 30 nM for c-Src, Yes, Lck and Abl, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 53 | In Stock |
|
| 25MG | 87 | In Stock |
|
| 50MG | 133 | In Stock |
|
| 100MG | 215 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSaracatinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, highly selective, orally available, dual Src/Abl kinase inhibitor with IC50 of 2.7, 4, 4 and 30 nM for c-Src, Yes, Lck and Abl, respectively.
-
DescriptionA potent, highly selective, orally available, dual Src/Abl kinase inhibitor with IC50 of 2.7, 4, 4 and 30 nM for c-Src, Yes, Lck and Abl, respectively; displays high selectivity over a range of kinases (Csk, VEGFR-2, Flt-4, EGFR, and PDGFR); exhibits potent inhibition of tumor growth in a c-Src-transfected 3T3-fibroblast xenograft model in vivo.Breast Cancer Phase 2 Clinical
-
SynonymsAZD0530;AZD-0530;AZD 0530
-
PathwayAngiogenesis
-
TargetSrc
-
RecptorBLK;c-Kit;c-Src;c-Yes;EGFR;EGFR(L858R);EGFR(L861Q);EphA2;FGR;Fyn;Lck;Lyn;v-Abl;EGFRL861Q;EGFRL858R
-
Research AreaCancer
-
IndicationBreast Cancer
Chemical Information
-
CAS Number379231-04-6
-
Formula Weight542.03
-
Molecular FormulaC27H32ClN5O5
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 32 mg/mL
-
SMILESCN1CCN(CCOC2=CC3=NC=NC(NC4=C5OCOC5=CC=C4Cl)=C3C(OC6CCOCC6)=C2)CC1
-
Chemical Name4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hennequin LF, et al. J Med Chem. 2006 Nov 2;49(22):6465-88.
2. Herynk MH, et al. Mol Cancer Ther. 2006 Dec;5(12):3023-31.
3. Chang YM, et al. Oncogene. 2008 Oct 23;27(49):6365-75.
4. Gwanmesia PM, et al. BMC Cancer. 2009 Feb 13;9:53.
2. Herynk MH, et al. Mol Cancer Ther. 2006 Dec;5(12):3023-31.
3. Chang YM, et al. Oncogene. 2008 Oct 23;27(49):6365-75.
4. Gwanmesia PM, et al. BMC Cancer. 2009 Feb 13;9:53.
molnova catalog
related products
-
KX2-361
KX2-361 (KX 02) is a potent, dual Src signaling/tubulin polymerization inhibitor that are under clinical evaluation.
-
Saracatinib
A potent, highly selective, orally available, dual Src/Abl kinase inhibitor with IC50 of 2.7, 4, 4 and 30 nM for c-Src, Yes, Lck and Abl, respectively.
-
WAY-303290
WAY-303290 inhibits the pY binding site of tyrosine kinase p56lck SH2 domain.
